Focus on including foods high in calories, protein, and nutrients into your loved one’s diet when they are experiencing ...

The company reported a net loss attributable to common stockholders of $5.7 million, or $1.99 per share, for the three months ended June 30, 2025, compared to a net loss attributable to common ...

With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent ...

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

Genmab Announces Financial Results for the First Half of 2025August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025HighlightsEpcoritamab advancing to earlier lines ...

Key opinion leader event and pancreatic cancer clinical data validate decision to engage with regulators on plans for a registration-enabling study New members of the ...

Researchers have found that a common tool used by clinicians for predicting kidney failure could be underestimating the risk ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.

Epkinly with Rituxan and Revlimid, compared to Rituxan and Revlimid alone, reduced risk of progression or death by 79%.

Since 1990, the global incidence of early-onset cancer has risen by 80 percent. Oncologists share what's behind the rising ...